{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Strict Complete Response (sCR)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Complete response (CR)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Very Good Partial Response (VgPR)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Partial Response (PR)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"}],"units":"Participants"}],"description":"To determine response rate (Strict Complete Response (sCR), Complete response (CR), Very Good Partial Response (VgPR), and Partial Response (PR)) in multiple myeloma patients receiving oral fenofibrate therapy. Response will be measured by serum and urine protein electrophoresis and immunofixation, as well as by percentage of plasma cells present on bone marrow biopsy.","groups":[{"description":"Fenofibrate orally daily for each 28 day cycle, per study protocol.\n\nFenofibrate: Upon screening, registration and enrollment, all subjects will receive Fenofibrate 160 mg orally daily for at least 2 months and may continue receiving study medication for as long as in the opinion of the investigator there is clinical benefit in doing so. Patients with calculated creatinine clearance \\< 50 mL/min will receive a reduced dose of 54 mg orally daily.","id":"OG000","title":"Fenofibrate Therapy"}],"paramType":"NUMBER","populationDescription":"No participants achieved response to protocol therapy (Strict Complete Response (sCR), Complete response (CR), Very Good Partial Response (VgPR), or Partial Response (PR)). Two (2) patients had stable disease (SD); one (1) patient achieved Stable Disease/clinical Progressive Disease, and three (3) patients had progressive disease (PD).","reportingStatus":"POSTED","timeFrame":"After two cycles, about 2 months","title":"Rate of Response in Participants Receiving Fenofibrate Therapy","type":"PRIMARY","unitOfMeasure":"participants"}